8 November marks the one-year anniversary of ‘Pfizer Monday’ – when stockmarkets surged following the news that Pfizer and BioNTech’s coronavirus vaccine was 90% effective in trials.
The increased likelihood that life would once again return to normal caused the MSCI All-Country World index to surpass its previous record high, while the FTSE 100 saw its biggest single-day jump since before the pandemic. It was after this that the ‘growth-versus-value' debate reared its head, with sectors that were particularly hard hit by Covid, as well as cyclical stocks, experiencing rapid rebounds. In an IW article published less than a week after the Pfizer announcement, Antipodes Partners' client portfolio manager Alison Savas said investors who "continue pouring into growth...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
